Zevra Therapeutics is trading 5.14% higher at $10.02, with the move occurring alongside sector and market strength rather than a confirmed company-specific catalyst. - On October 27, 2026, XBI was reported up 2.18% during the regular session, amid broadly positive market sentiment. - No fresh company-specific announcement explaining the gain was found; Zevra Therapeutics’ next scheduled update is its third-quarter results on November 3.